in bone marrow core biopsies of patients with hairy cell leukemia (HCL) after treatment with 2-chlorodeoxyadenosine (2-CdA) using immunohistochemical (IHC) techniques. The purpose of this study was to determine whether the presence of MRD predicts bone marrow relapse. We studied paraffinembedded bone marrow core biopsies from 39 patients with HCL in complete remission (CR) 3 months after a single cycle of 2-CdA. Biopsies performed 3 months posttherapy and annually thereafter were examined by routine hematoxylin and eosin (H&E) staining and IHC using the monoclonal antibodies (MoAbs) anti-CD45RO. anti-CD20, and DBA.44. At 3 H AIRY CELL LEUKEMIA (HCL) is an uncommon chronic B-cell lymphoproliferative disorder characterized by splenomegaly and pancytopenia.' This disease has received increased attention due to the development of effective therapies such as the purine analogs 2-deoxycoformycin (Pentostatin; Parke-Davis, Moms Plains, NJ) and 2-chlorodeoxyadenosine (2-CdA; Leustatin; Cladribine). In particular, 2-CdA is effective for HCL, inducing complete remission (CR) in approximately 80% of patients with newly diagnosed or previously treated disease.24 The remarkable efficacy of 2-CdA in the treatment of HCL has led to the examination of posttreatment bone marrow biopsies to identify minimal residual disease (MRD).
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We and others have reported the usefulness of immunohistochemistry (IHC) to detect MRD not evident by routine morphology in bone core biopsies from patients with HCL after treatment with 2-CdA.5s6 In these reports, paraffin-embedded biopsies have been studied using anti-CD20 and DBA.44 antibodies to identify cells with the morphology of hairy cells. DBA.44 is a monoclonal antibody that recognizes some B-cell lymphomas and is reactive with hairy cells. 7 The purpose of this study was to determine whether the presence of MRD in patients in remission by routine morphologic examination at 3 months after treatment with 2-CdA predicts subsequent bone marrow relapse.
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OOW-497I/96/8704-00l1$3.00/0 1556 months after therapy, 5 of 39 (13%) patients had MRD detectable by IHC that was not evident by routine H&E staining. Two of the five patients (40%) with MRD at 3 months have relapsed, whereas only 2 of 27 (7%) patients with no MRD and at least 1 year of follow up relapsed (P = .11). Over the 3-year follow-up period, two additional patients developed MRD. Overall, three of six (50%) patients with MRD detected at any time after therapy have relapsed, whereas only 1 of 25 (4%) patients without MRD has relapsed (P = .016). These data suggest that the presence of MRD after treatment with 2-CdA may predict relapse.
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versity (Chicago, IL) between February 1991 and January 1995 who achieved a CR 3 months after treatment with 2-CdA (Ortho Biotech, Raritan, NJ). Each patient received a single cycle of 2-CdA at a dose of 0.1 mgkg/d by continuous infusion for 7 days. Unilateral bone marrow core biopsies were performed 3 months after therapy and annually thereafter. At 3 months after treatment, 8 of 47 patients had either no biopsy or technically inadequate material for evaluation and were omitted from the study. Therefore, a total of 39 patients in CR at 3 months by routine morphology were included in this study (Table 1) . Paraffin-embedded bone marrow core biopsies from these 39 patients were evaluated by both routine staining techniques and IHC to detect MRD.
Immunohistochemistry. Bone marrow core biopsies obtained at Northwestern University were fixed in B5 for 90 minutes, decalcified in RDO (Apex Engineering Product Corp. Plainfield, L), dehydrated in graded alcohols and xylene, and embedded in paraffin. Tissue blocks of paraffin-embedded bone marrow core biopsies or precut tissue sections from referral institutions were sent to Northwestern University for immunohistochemical processing and evaluation. Immunohistochemical studies using the monoclonal antibodies (MoAbs) anti-CD20 (lineage-specific pan B-cell marker), anti-CD45RO (pan-T-cell marker), and DBA.44 were performed at Northwestem University by the method previously described." The slides were then examined by light microscopy. Establishment of negative controls. Paraffin-embedded bone marrow core biopsies from 10 patients undergoing evaluation for nonhematologic malignancies were studied to establish the B-to-T lymphocyte ratio and to examine the range of morphology exhibited by immunostained B and T lymphocytes. Control biopsies were evaluated using MoAbs anti-CD4SR0, anti-CD20, and DBA.44. Quantitation of B and T lymphocytes per bone core biopsy was performed by counting CD45RO-, CD20-, and DBA.44-positive cells per 500 bone marrow cells.
Dejnition of MRD. The criteria for MRD used in this study represent a refined version of those that have been published p=-viously5 and require (1) the absence of HCL by routine morphology of peripheral blood, aspirate, and hemotoxylin and eosin (H&E)-stained bone marrow core sections; (2) Definition of relapse of bone marrow disease. Relapse of bone marrow disease was diagnosed when HCL was present on routine evaluation of H&E-stained bone marrow core biopsies, with or without identifiable hairy cells on peripheral blood and bone marrow aspirate.
Sratistical analysis. Statistical comparisons of the data were performed using the Fisher exact test.
RESULTS
Analysis of negative controls. CD45RO-positive cells (T cells) were present in all 10 biopsies and comprised a mean of 4.8% (range, 2.6% to 7.0%) of the total bone marrow cells. CD20-and DBA.44-positive cells (B cells) were present in approximately equal numbers in all 10 biopsies and comprised a mean of 1.5% (range, 0.4% to 3.6%) and 1.6% (range, 0.8% to 2.8%) of the total bone marrow cells, respec-1557 tively. Overall, in the control bone core biopsies, CD45RO-positive cells were consistently more numerous than CD20-or DBA.44-positive cells, with a quantitative T cell-to-B cell ratio of approximately 3: 1. CD45RO-, CD20-, and DBA.44-positive cells had similar morphologic features and exhibited round, condensed nuclei, scant cytoplasm, and smooth cytoplasmic borders (Fig 1) . However, there were rare positive cells identified by all MoAbs that had abundant cytoplasm and irregular cytoplasmic borders similar to the morphology of hairy cells.
Morphology of hairy cells. Hairy cells were identified as CD20-or DBA.44-positive cells with moderate to abundant cytoplasm and distinct cytoplasmic projections that were best visualized when the cells were separate from one another. The nuclei appeared slightly enlarged and were round to oval with occasional nuclear indentations. CD20 demonstrated strong surface membrane positivity, whereas DBA.44 exhibited both cytoplasmic and surface membrane positivity. CD20 produced a delicate, crisp outline of the cytoplasmic villous projections and allowed visualization of the nuclear features (Fig 2) . DBA.44 also amplified the cytoplasmic details and hairy projections; however, it tended to obscure the nuclear detail due to the intense cytoplasmic reactivity (Fig  2) . CD20 and DBA.44 detected approximately equal numbers of hairy cells in all neoplastic biopsies. The differentiation of neoplastic hairy cells from other cells was not always definitive using IHC. This was related to many factors including thickness and level of tissue sections, variation in immunostaining intensity, and overlap of hairy cell morphology with other cells.
The pattern of residual hairy cells in bone marrow core biopsies usually consisted of individual cells scattered throughout the biopsy. Isolated hairy cells were present in an interstitial pattern; occasionally one or multiple small aggregates of hairy cells were present.
MRD after 2-C&. At 3 months, 5 of 39 (13%) patients had MRD identified by IHC. All five patients with MRD and 27 patients with no MRD at 3 months had at least one annual follow-up bone marrow biopsy (Table l) . Two of the five (40%) patients with MRD at 3 months have relapsed (patients 14 and 22), whereas only 2 of 27 (7%) patients without MRD at 3 months have relapsed (P = .l 1 ; median follow up, 24 months in each group).
Among the three patients with MRD at 3 months who did not relapse, patients 1 and 16 continue to have MRD at 3 years and 2 years, respectively. The third patient (patient 2) had MRD in a hypocellular bone marrow (less than 5% cellularity) at 3 months; however, three subsequent annual biopsies, also markedly hypocellular, have been negative.
Among the two patients without MRD at 3 months who have relapsed, one patient (patient 23) relapsed at 1 year, and one patient (patient 15) relapsed at 2 years. Patient 15 had a 3-month biopsy that was essentially aplastic, with rare cells that resembled hairy cells by IHC. The 3-month biopsy did not meet criteria for MRD; however, the l-year biopsy demonstrated MRD in a 25% cellular marrow, and the subsequent biopsy at 2 years showed relapse. Patient 23 relapsed without previous evidence of MRD. One additional patient For personal use only. on October 22, 2017. by guest www.bloodjournal.org From 
(patient 3) developed MRD 3 years after diagnosis but has
Overall, a total of 7 of the 39 (18%) patients in this study not had a follow-up biopsy at the time of this report. All have demonstrated MRD regardless of time of biopsy after patients who relapsed subsequently developed progressive treatment with 2-CdA over a 3-year period. Of those with cytopenias requiring treatment. None of the eight patients at least one follow-up biopsy, three of six (50%) patients excluded from this study because of inadequate material at with MRD have relapsed versus 1 of 25 patients without 3 months have relapsed.
MRD (P = .016). For personal use only. on October 22, 2017. by guest www.bloodjournal.org From DISCUSSION 2-CdA is emerging as an extremely effective treatment for patients with HCL due to the high CR rates and low toxicity associated with a single cycle of therapy. Although most patients remain in sustained remission, it appears that relapse occurs in a small number of patients8 Therefore, it may be important to identify patients at risk for early relapse in whom a second course of 2-CdA or an alternative therapy may be beneficial. We have previously shown that MRD can be detected in bone marrow core biopsies by IHC in a small number of patients who are in CR as detected by routine m~rphology.~ The present study expands on these initial observations and is the first to suggest that MRD after treatment with 2-CdA may predict bone marrow relapse.
The results reported here confirm our initial observations that only a small percentage of patients have MRD 3 months after treatment with 2-CdA. The incidence of MRD at 3 months is important because bone marrow biopsies are routinely performed at this timepoint after 2-CdA. Although the small number of patients in this study limits the ability to demonstrate statistical significance, 40% of patients with MRD at 3 months have relapsed, compared with only 7% of patients without MRD (P = . l 1). When all biopsies with MRD were analyzed regardless of timepoint, 50% of patients with MRD and at least one follow-up biopsy relapsed, compared with only 4% of patients without MRD (P = .016).
Thus, it appears that our criteria for MRD may identify a subset of patients at risk for relapse.
Not all patients with MRD relapsed. In this study, MRD persisted in two patients for 1 to 2 years without overt relapse, which may reflect the fact that HCL is a particularly indolent disease. An additional patient with MRD in an aplastic biopsy at 3 months had apparent regression of disease. This could reflect a prolonged time to CR after therapy or may indicate the difficulty of evaluating MRD in aplastic bone marrow biopsies.
The criteria for MRD used in the current study are conservative. These criteria were established to avoid overestimating the number of neoplastic cells, because MoAbs anti-CD20 and DBA.44 are not specific for hairy cells, and because CD20-and DBA.44-positive cells were present in all non-neoplastic control biopsies. Because all MoAbs used in the control biopsies highlighted rare cells with morphology similar to hairy cells, we did not feel that the presence of only isolated cells with the morphology of hairy cells was sufficient to define MRD. Therefore, our criteria for MRD required that greater than 50% of CD20-or DBA.44-positive cells exhibit the morphology of hairy cells. We also required that cells marking as B cells by IHC be equal to or more numerous than those marking as T cells. This was based on our study of control biopsies, as well as other reports that T cells exist in greater numbers than B cells in non-neoplastic biopsies.' This helped ensure that the number of B cells present were sufficient for morphologic evaluation and that an increase in B cells was not part of a reactive B-and Tcell hyperplasia. Although these criteria may underestimate the true incidence of MRD, they may detect a threshold of MRD that has clinical importance.
Several other groups have demonstrated detection of residual disease in patients with HCL after therapy with 2-CdA; however, the criteria used to define residual disease have not been u n i f~r m .~. '~'~ Bastie et a l l 0 used IHC to monitor disease in 28 patients with HCL treated with a single cycle of 2-CdA. In that study, residual disease was defined as 1% to 5% DBA.44-positive cells in bone marrow biopsies with no evidence of hairy cells by routine morphologic examination. At 6 months, 8 of 22 (36%) patients in CR had residual disease by IHC. Long-term follow up was not available to evaluate how many of these patients relapsed. Pileri et all' applied anti-CD20 and DBA.44 to bone marrow biopsies from 32 patients and evaluated residual disease using the hairy cell index (HCl).I4 Although the investigators demonstrated a marked decrease in the HC1 after treatment with 2-CdA, they did not identify an immunohistologic pattern predictive of disease progression or relapse.
Ellison et a16 recently reported the use of MoAbs to identify MRD in bone marrow biopsies from patients with HCL treated with 2-CdA. The investigators defined MRD as five or more CD20-or DBA.44-positive cells with morphology of hairy cells per bone core biopsy. By these criteria, 47% of the 3-to 4-month biopsies and 50% of the total biopsies in their study showed MRD. This is in contrast with only a 13% incidence of MRD in 3-month biopsies and 7% of total biopsies in the present study. The marked difference in results of these two studies is likely due to the definitions of MRD. It is conceivable that small numbers of hairy cells identified by IHC in the report of Ellison et a16 may, in fact, accurately represent MRD. However, the level of disease detected may not be clinically meaningful for many years. In fact, the majority of bone core biopsies in that study showed stable numbers of residual hairy cells over time. Longer follow-up will be necessary to determine whether or not their criteria for MRD correlate with early bone marrow relapse.
Other investigators have used Southern blot or polymerase chain reaction (PCR) techniques to detect residual disease in HCL patients treated with 2-CdA and have reported disparate results. Di Celle et all2 used Southern blot to analyze the heavy-chain immunoglobulin gene (IgH) configuration of six patients with HCL after 2-CdA therapy and demonstrated no evidence of IgH rearrangements in all four patients in CR. In contrast with these findings, Filleul et all3 used PCR and IgH-or T-cell receptor delta-derived clonospecific probes to detect MRD in 10 patients and demonstrated persistent disease in all assessable patients in CR.
A variety of sophisticated techniques now suggest that HCL may not be completely eradicated by a single cycle of 2-CdA. However, the significance of detecting residual disease is not clear. Our data suggest that the presence of MRD by IHC may predict relapse. If these observations are verified by long-term follow up, it is possible that patients may benefit from a second cycle of 2-CdA or an alternative approach early in the disease course to increase the likelihood of cure. For personal use only. on October 22, 2017. by guest www.bloodjournal.org From
